Kerry A. Pierce
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kerry A. Pierce has a total of 141 co-authors. Here are the top co-authors by number of shared publications:
- Clary B. Clish
Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA
65 shared publications - Vamsi Krishna Mootha
Department of Molecular Biology, Massachusetts General Hospital, Boston, USA
59 shared publications - Adam S. Fisch
Massachusetts General Hospital 1 Department of Pathology Boston, Massachusetts
57 shared publications - Apekshya Panda
Broad Institute of MIT and Harvard, Cambridge, Massachusetts
57 shared publications - Benjamin J. Gigliotti
Division of Endocrinology, Diabetes, and Metabolism, University of Rochester Medical Center Rochester, New York
57 shared publications - Bryn Reimer
University of Massachusetts Amherst
57 shared publications
Latest Publications
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S7 from Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma
Supplementary Figure 1: Mitochondrial and nuclear DNA alterations in an HCC cohort. Related to Figure 1. Supplementary Figure 2: Transcriptomic landscape of HCC. Related to Figure 2. Supplementary Figure 3: Metabolic signatures of HCC. Related to Figure 3. Supplementary Figure 4: Authentic models of HCC. Related to Figure 4. Supplementary Figure 5: CRISPR screen identifies vulnerability to GPX4 loss in HCC. Related to Figure 5. Supplementary Figure 6: NCI-HCC xenografts are sensitive to ferroptosis. Related to Figure 6. Supplementary Figure 7: Differential effects of OXPHOS inhibition on ferroptosis. Related to Figure 7.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S7 from Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma
Supplementary Figure 1: Mitochondrial and nuclear DNA alterations in an HCC cohort. Related to Figure 1. Supplementary Figure 2: Transcriptomic landscape of HCC. Related to Figure 2. Supplementary Figure 3: Metabolic signatures of HCC. Related to Figure 3. Supplementary Figure 4: Authentic models of HCC. Related to Figure 4. Supplementary Figure 5: CRISPR screen identifies vulnerability to GPX4 loss in HCC. Related to Figure 5. Supplementary Figure 6: NCI-HCC xenografts are sensitive to ferroptosis. Related to Figure 6. Supplementary Figure 7: Differential effects of OXPHOS inhibition on ferroptosis. Related to Figure 7.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary_Table1 from Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma
Supplementary Table 1 describes the HCC clinical cohort
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary_Table1 from Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma
Supplementary Table 1 describes the HCC clinical cohort
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary_Table5 from Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma
Supplementary Table5 provides the CRISPR screen results
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary_Table5 from Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma
Supplementary Table5 provides the CRISPR screen results
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary_Table3 from Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma
Supplementary Table3 provides the RNAseq analysis
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary_Table3 from Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma
Supplementary Table3 provides the RNAseq analysis
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary_Table2 from Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma
Supplementary Table 2 provides the mtDNA and LOH analyses
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary_Table2 from Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma
Supplementary Table 2 provides the mtDNA and LOH analyses
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary_Table4 from Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma
Supplementary Table4 provides the metabolomics analysis
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary_Table4 from Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma
Supplementary Table4 provides the metabolomics analysis
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary_Table1 from Effectors enabling adaptation to mitochondrial complex I loss in Hurthle cell carcinoma
Supplementary Table 1 describes the HCC clinical cohort
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary_Table1 from Effectors enabling adaptation to mitochondrial complex I loss in Hurthle cell carcinoma
Supplementary Table 1 describes the HCC clinical cohort
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary_Table5 from Effectors enabling adaptation to mitochondrial complex I loss in Hurthle cell carcinoma
Supplementary Table5 provides the CRISPR screen results
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary_Table5 from Effectors enabling adaptation to mitochondrial complex I loss in Hurthle cell carcinoma
Supplementary Table5 provides the CRISPR screen results
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary_Table4 from Effectors enabling adaptation to mitochondrial complex I loss in Hurthle cell carcinoma
Supplementary Table4 provides the metabolomics analysis
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary_Table4 from Effectors enabling adaptation to mitochondrial complex I loss in Hurthle cell carcinoma
Supplementary Table4 provides the metabolomics analysis
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S7 from Effectors enabling adaptation to mitochondrial complex I loss in Hurthle cell carcinoma
Supplementary Figure 1: Mitochondrial and nuclear DNA alterations in an HCC cohort. Related to Figure 1. Supplementary Figure 2: Transcriptomic landscape of HCC. Related to Figure 2. Supplementary Figure 3: Metabolic signatures of HCC. Related to Figure 3. Supplementary Figure 4: Authentic models of HCC. Related to Figure 4. Supplementary Figure 5: CRISPR screen identifies vulnerability to GPX4 loss in HCC. Related to Figure 5. Supplementary Figure 6: NCI-HCC xenografts are sensitive to ferroptosis. Related to Figure 6. Supplementary Figure 7: Differential effects of OXPHOS inhibition on ferroptosis. Related to Figure 7.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S7 from Effectors enabling adaptation to mitochondrial complex I loss in Hurthle cell carcinoma
Supplementary Figure 1: Mitochondrial and nuclear DNA alterations in an HCC cohort. Related to Figure 1. Supplementary Figure 2: Transcriptomic landscape of HCC. Related to Figure 2. Supplementary Figure 3: Metabolic signatures of HCC. Related to Figure 3. Supplementary Figure 4: Authentic models of HCC. Related to Figure 4. Supplementary Figure 5: CRISPR screen identifies vulnerability to GPX4 loss in HCC. Related to Figure 5. Supplementary Figure 6: NCI-HCC xenografts are sensitive to ferroptosis. Related to Figure 6. Supplementary Figure 7: Differential effects of OXPHOS inhibition on ferroptosis. Related to Figure 7.